Pier Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Pier Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,118	Closed	-$608K	–	127
2014 Q4	$608K	Sell	5,118 -795	-13%	-$89.5K	0.09%	100
2014 Q3	$664K	Buy	5,913 +2,675	+83%	+$255K	0.11%	101
2014 Q2	$307K	Buy	+3,238	New	+$227K	0.04%	113

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pier Capital's VRTX Position: Q1 2015 in Review

Pier Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2015, closing a stake of 5,118 shares — an estimated $608K sold.

Pier Capital first reported a position in VRTX in Q2 2014 and held it in 3 quarters. The position peaked at $664K in Q3 2014. 479 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

Pier Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Pier Capital sold 5,118 Vertex Pharmaceuticals shares in Q1 2015, an estimated $608K.
Pier Capital first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Pier Capital's Vertex Pharmaceuticals position peaked at $664K in Q3 2014.
479 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Pier Capital's 13F filing for Q1 2015, filed 14 May 2015.